Inhibitors: Prevention, Eradication, and Lived Experiences

Inhibitor development has long been considered the most significant complication of severe hemophilia, but with the licensure of the first non-factor therapy and a robust pipeline of novel and gene therapeutics being investigated, is it still of critical importance that we better understand inhibitors? If so, what research is currently taking place, and what can he hope to learn from it? This episode of the Global Hemophilia Report from BloodStream Media features contributions and citations from investigators, clinicians, and research funders dedicated to this topic, as well as from patients and caregivers who can speak to their lived experience of inhibitors.   For more on inhibitor research: Inhibitors and Hemophilia - CDC ATHN 8: PUPs Matter Study - ATHN The Hemophilia Inhibitor Eradication Trial - ClinicalTrials.gov A New Plan for Tackling Inhibitors - NHF ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders - ASH The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development - ASH   Show Notes: Featured Advertiser: Sanofi Genzyme Subscribe to BloodStream Media's Global Hemophilia Report Senior Adviser: Dr. Donna DiMichele   Connect with the Global Hemophilia Report Global Hemophilia Report on LinkedIn Global Hemophilia Report on Twitter Global Hemophilia Report on Facebook   Connect with BloodStream Media: BloodStreamMedia.com BloodStream on Facebook  BloodStream on Twitter